In particular, FLT3-TKD mutant clones could be selected from in vitro saturation mutagenesis assay [30] and found in FLT3-ITD AML cell lines treated with increasing dose of FLT3 inhibitors for 6–7 weeks [31]. The gene discussed is FLT3; the disease is acute myeloid leukemia.